Bristol Myers: gastrointestinal cancer results

(CercleFinance.com) - Bristol Myers Squibb has presented CheckMate-648 data showing that Opdivo plus chemotherapy and Opdivo plus Yervoy significantly improve overall survival compared to chemotherapy in advanced or metastatic unresectable esophageal squamous cell carcinoma.


"Opdivo demonstrated significant overall survival benefit over chemotherapy alone in both PD-L1 positive and all-randomized populations in both treatment arms," the group said.

"CheckMate -648 marks the third global trial in which Opdivo demonstrated a significant benefit for patients with upper gastrointestinal cancers," it added.

The data will be presented orally at the American Society of Clinical Oncology (ASCO) annual meeting in 2021.


Copyright (c) 2021 CercleFinance.com. All rights reserved.